DelveInsight’s “Metastatic Triple Negative Breast Cancer (mTNBC)” report delivers an in-depth understanding of the Metastatic Triple Negative Breast Cancer (mTNBC), historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer  market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

 

Key Highlights from the Metastatic Triple Negative Breast Cancer Market Report: 

• Total Diagnosed Incident cases of Triple Negative Breast Cancer in the 7MM countries was 99,380 in 2017.
• Amongst the EU-5 countries (Germany, France, the United Kingdom, Spain, and Italy), Germany had the highest diagnosed incidence of TNBC followed by France and Italy in the year 2017.
• Out of the total cases of Triple Negative Breast Cancer, more than 8000 cases were in the advanced stage in the US in 2017.

• Key Pipeline therapies in the Metastatic Triple Negative Breast Cancer market are Ipatasertib (Hoffman-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (Cytodyn), and others anticipated to enter the market in the next decade.
• Key companies proactively working in the mTNBC market include Hoffman-La Roche, Infinity Pharmaceuticals, Cytodyn, among others.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-market

 

Metastatic Triple Negative Breast Cancer (mTNBC) market report provides current treatment practices, emerging drugs, Metastatic Triple Negative Breast Cancer (mTNBC) market share of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy market Size from 2018 to 2030 segmented by seven major markets. 

The Report also lays forward current mTNBC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Metastatic Triple Negative Breast Cancer: Disease Overview

Metastatic Triple Negative Breast Cancer is characterized as a metastatic tumor in which the estrogen and progesterone (ER/PR) receptors are negative by immunohistochemistry (IHC) and there is no overexpression of HER2 by immunohistochemistry (IHC) or no gene amplification by fluorescence in situ hybridization technique. TNBC (ER-PR-HER2-) and other breast cancers have different epidemiological risk factor profiles.

According to breastcancer.org, about 70% of breast cancers diagnosed in people who have an inherited BRCA mutation, particularly BRCA1, are triple-negative.

TNBCs are slightly larger and of higher grade than non-TNBCs, according to secondary sources, but they are less likely to have lymph node metastases.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-market

 

Metastatic Triple Negative Breast Cancer Market

• Market Size of mTNBC in the 7MM was USD 438 Million in 2017.
• Among the EU-5 countries, Germany accounted for the highest market size for mTNBC in 2017
• The United States accounted for the largest mTNBC market size, in comparison to the other 7MM countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), Japan.
• The mTNBC market size of the first line of therapy (LoT) was estimated to be higher than that of the second line of therapy.

 

Metastatic Triple Negative Breast Cancer Treatment Landscape 

Currently, the treatment paradigm for mTNBC includes few treatment options such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery and radiation.

Few US FDA approved drugs, such as:

• Keytruda (Pembrolizumab): Merck Sharpe and Dohme
• Lynparza (Olaparib): AstraZeneca
• Tecentriq (Atezolizumab): Hoffmann-La Roche
• Talzenna (talazoparib): Pfizer
• Trodelvy: Gilead Sciences.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-market

 

Various off label drugs are used for treating mTNBC which include: 

• Paclitaxel (Abraxane)
• Erbulin (Halaven)
• Carboplatin
• Cisplatin
• Docetaxel 

 

Metastatic Triple Negative Breast Cancer Market is expected to witness the launch of upcoming therapies by key pharmaceutical companies including Hoffman-La Roche, Infinity Pharmaceuticals, Cytodyn, and several others. The launch of Ipatasertib (Hoffman-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (Cytodyn), etc. is anticipated to provide a major push to the growth of the mTNBC market size in the forecast period 2018-30 in the 7MM. 

 

Learn more about market insights @ https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-market

 

Metastatic Triple Negative Breast Cancer Emerging Drugs

• Ipatasertib (RG7440): Hoffmann-La Roche 
• IPI-549 (Eganelisib): Infinity Pharmaceuticals
• Pembrolizumab (Imprime PGG): HiberCell
• Leronlimab (PRO 140): CytoDyn
• CFI-400945: Treadwell Therapeutics

 

Metastatic Triple Negative Breast Cancer Market Drivers

• Advancements in Genomics and Proteomics
• Emergence of Immunotherapies
• Improved Treatment Deliverance
• Increase in Number of Research Articles

 

Metastatic Triple Negative Breast Cancer Market Barriers

• Use of Off Label Therapies and Generics
• High Treatment Cost
• Fewer Patients Available for Clinical Trials
• High Recurrence Rate
• Multiple Treatment Challenges 

 

 

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Key Companies in mTNBC Market: Hoffmann-La Roche, Infinity Pharmaceuticals, HiberCell, CytoDyn, Treadwell Therapeutics, and several others. 

Key mTNBC Pipeline therapies: Ipatasertib (RG7440), IPI-549 (Eganelisib), Pembrolizumab (Imprime PGG), Leronlimab (PRO 140), CFI-400945 and several others.

mTNBC Market Segmentation: By Geography, By mTNBC therapies

Analysis: Comparative and conjoint analysis of mTNBC emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

 

Table of Contents

1.	Key Insights
2.	Triple Negative Breast Cancer Market Overview at a Glance
3.	Disease Background and Overview: Triple Negative Breast Cancer
4.	Unmet Needs
5.	Epidemiology and Patient Population
6.	Country Wise-Epidemiology of TNBC
7.	Treatment Practices
8.	Marketed Drug Analysis
9.	Emerging Therapies
10.	Metastatic Triple Negative Breast Cancer (mTNBC): 7MM Market Analysis
11.	Market Outlook by Country
12.	Market Drivers
13.	Market Barriers
14.	Appendix
15.	DelveInsight Capabilities
16.	Disclaimer
17.	About DelveInsight

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-market